All In Biotech

Drug Trial Radar · NCT05623020

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,060 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,060

Planned (sponsor's estimate)

Start

Nov 10, 2022

Primary completion

Oct 18, 2030

Study completion Oct 3, 2033

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in people with newly diagnosed multiple myeloma. There are 2 parts to this study. Part 1 will characterize the safety and tolerability of elranatamab in combination with daratumumab and lenalidomide or in combination with lenalidomide and will identify the optimal dose(s) of the combination regimen. Part 2 of the study will evaluate the rate of minimal residual disease (MRD) negative CR and the progression free survival (PFS) of the combination of elranatamab, daratumumab, and lenalidomide compared with the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • ElranatamabDrug

    Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

  • DaratumumabDrug

    Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

  • LenalidomideDrug

    Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

  • DexamethasoneDrug

    Randomized

  • BortezomibDrug

    Randomized

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Dose Limiting ToxicityTime frame: From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide
  2. Part 2: Progression free survival per IMWGTime frame: From randomization up to 97 months.
  3. Part 2: Minimal Residual Disease negative CR rateTime frame: At 12 months after randomization

Locations

180 sites in 25 countries. Site status is shown where the registry gives one.

  • Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Malbis

    Daphne, Alabama · Recruiting

  • Gulf Health Hospitals, Inc. d/b/a Thomas Medical Center

    Daphne, Alabama · Recruiting

  • Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Fairhope

    Fairhope, Alabama · Recruiting

  • Mobile Infirmary Association d/b/a Mobile Infirmary Medical Center

    Mobile, Alabama · Recruiting

  • Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Mobile

    Mobile, Alabama · Recruiting

  • Mobile Infirmary Medical Center

    Mobile, Alabama · Recruiting

  • Mobile Infirmary Association d/b/a Mobile Infirmary Medical Center.

    Mobile, Alabama · Recruiting

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

    Coral Gables, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Coral Springs

    Coral Springs, Florida · Recruiting

  • University of Miami Hospital and Clinics Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center- Doral

    Doral, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Hollywood

    Hollywood, Florida · Recruiting

  • Jupiter Medical Center/Anderson Family Cancer Institute

    Jupiter, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center Kendall

    Miami, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Sole Mia

    North Miami, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center - Plantation

    Plantation, Florida · Recruiting

  • NHO Revive Research Institute, LLC

    Lincoln, Nebraska · Recruiting

  • Renown Health Medical Oncology

    Reno, Nevada · Recruiting

  • Renown Office of Clinical Research

    Reno, Nevada · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • MSK Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • MSK Monmouth

    Middletown, New Jersey · Recruiting

  • MSK Bergen

    Montvale, New Jersey · Recruiting

  • MSK Commack

    Commack, New York · Recruiting

  • MSK Westchester

    Harrison, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center-Main Campus

    New York, New York · Recruiting

  • MSK Nassau

    Uniondale, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • LDS Hospital

    Salt Lake City, Utah · Recruiting

  • Intermountain Cancer Center St. George

    St. George, Utah · Recruiting

  • St. George Regional Hospital

    St. George, Utah · Recruiting

  • Hospital Privado Universitario de Córdoba

    Córdoba, Córdoba Province, Argentina · Not yet recruiting

  • Sanatorio de La Mujer

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • Pindara Private Hospital

    Benowa, Queensland, Australia · Recruiting

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Epworth Freemasons

    Melbourne, Victoria, Australia · Recruiting

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.